Apellis Pharmaceuticals, Inc. — Director's Dealing 2020

May 12, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2020-05-08

Reporting Person: FONTEYNE PAUL R. (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-05-08	Common Stock	P	5000	$31.8068	Acquired	5000	Direct

Footnotes

F1: Open market purchase.